TRI group TFI group
Number of patients [n (%)] 340(51.56) 321(48.43)
Age (years) 64.5±9.74 65.9±12.8
Male gender [n (%)] 264(77.64) 253(75.7)
Systemic hypertension [n (%)] 176(51.76) 163(50.77)
Diabetes mellitus [n (%)] 115(33.82) 104(32.39)
Hypercholesterolemia [n (%)] 100(29.41) 97(30.21)
Current smoker [n (%)] 191(56.17) 180(56.07)
Previous MI [n (%)] 21(6.17) 19(5.91)
Location of MI    
Anterior [n (%)] 188(55.29) 171(53.27)
Inferior or posterior [n (%)] 152(44.7) 150(46.72)
Killip Class    
I [n (%)] 215(63.23) 201(62.61)
II [n (%)] 79(23.23) 73(22.74)
III or IV [n (%)] 46(13.52) 47(14.64)
Concomitant therapy    
Aspirin [n (%)] 335(98.52) 318(99.06)
Clopidogrel [n (%)] 336(98.82) 319(99.37)
Beta-blocker [n (%)] 311(91.47) 296(92.21)
ACEI/ARB [n (%)] 298(87.64) 274(85.35)
Statin [n (%)] 322(94.7) 299(93.14)
Values are presented as mean ± standard deviation or n (%).
*Denotes statistical difference (p < 0.05) compared to normal group.
TRI,transradial intervention;TFI,transfemoral intervention; MI, myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB,angiotensin receptor blocker
Table 1: Baseline characteristics of study population.